Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 4 of 59, showing 5 Applications out of 292 total, starting on record 16, ending on 20

# Protocol No Study Title Investigator(s) & Site(s) Application Status

16.

ECCT/21/05/06   VAC52150EBL2010 ;Phase 2
    An open label, Phase 2 study to evaluate the safety and immunogenicity of an Ad26.ZEBOV booster dose in Human Immunodeficiency Virus Positive (HIV+) adults previously vaccinated with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen   
Principal Investigator(s)
1. Prof. Omu Anzala Omu Anzala
Site(s) in Kenya
KAVI-institute of Clinical Research
 
Trial Status (not set!)
Protocol Date 13-11-2020
View

17.

ECCT/21/05/03   Adapt Out COVID
    Adaptive Platform Treatment trial for Outpatients with COVID-19   
Principal Investigator(s)
1. Kawango Agot
Site(s) in Kenya
1. Kenya Impact and Research Development Organization (K-IRDO) (Kisumu county)
2. KEMRI WALTER REED (Kericho county)
3. MOI UNIVERSITY CLINICAL RESEARCH CENTRE (Uasin Gishu county)
4. Kenya Medical Research Institute (Kisumu county)
 
Trial Status Not yet recruiting
Protocol Date 22-12-2020
View

18.

ECCT/21/05/02   BFTAF Elderly Switch Study
    Switching virally suppressed HIV-1 infected elderly adults (age ≥ 60 years) without prior confirmed virological failure from current anti-retroviral regimen to bictegravir, emtricitabine and tenofovir alafenamide (B/F/TAF)   
Principal Investigator(s)
1. Loice Achieng Ombajo
Site(s) in Kenya
1. Kenyatta National Hospital (Nairobi City county)
2. Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county)
 
Trial Status (not set!)
Protocol Date 16-12-2020
View

19.

ECCT/21/03/03   PrEP My Way
    A Novel PrEP Delivery System to Meet the Needs of Young African Women   
Principal Investigator(s)
1. Prof. Elizabet Ann Bukusi
Site(s) in Kenya
Kisumu
 
Trial Status Recruiting
Protocol Date 29-10-2019
View

20.

ECCT/21/03/01   Recombinant COVID-19 vaccine
    A global multicenter, randomized, double-blind, placebo-controlled, phase III clinical trial to evaluate the efficacy, safety, and immunogenicity of recombinant COVID-19 vaccine (Sf9 cells), for the prevention of COVID-19 in adults aged 18 years and older   
Principal Investigator(s)
1. Walter Jaoko Jaoko
Site(s) in Kenya
KAVI-institute of Clinical Research
 
Trial Status (not set!)
Protocol Date 19-02-2021
View